MiMedx Group Inc (MDXG) : 6 analysts are covering MiMedx Group Inc (MDXG) and their average rating on the stock is 1.33, which is read as a Strong Buy. 5 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
MiMedx Group Inc (MDXG) : 6 investment research analysts covering MiMedx Group Inc (MDXG) have an average price target of $11.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $13 and the lowest target is $9 for the short term. Analysts expect the variance to be within $1.38 of the average price.
MiMedx Group Inc (NASDAQ:MDXG): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.98 and $7.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.07, notching a gain of 0.12% for the day. The total traded volume was 543,373 . The stock had closed at $8.06 on the previous day.
Also, In the latest statement by the brokerage house, Lake Street maintains its outlook on MiMedx Group Inc (NASDAQ:MDXG). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm lowers the price target from $15 per share to $12 per share. The rating by the firm was issued on April 19, 2016. The company shares have dropped -24.11% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $13.20 and the one year low was seen on May 13, 2016. The 50-Day Moving Average price is $7.70 and the 200 Day Moving Average price is recorded at $8.13.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.